Alpha Family Trust Acquires Shares of 1,695 Illumina, Inc. (NASDAQ:ILMN)

Alpha Family Trust acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the third quarter, HoldingsChannel.com reports. The fund acquired 1,695 shares of the life sciences company’s stock, valued at approximately $221,000.

A number of other institutional investors have also added to or reduced their stakes in the stock. Atlanta Consulting Group Advisors LLC purchased a new stake in Illumina during the 3rd quarter valued at approximately $257,000. Empowered Funds LLC grew its holdings in Illumina by 1.7% during the 3rd quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock valued at $516,000 after buying an additional 66 shares in the last quarter. Intellectus Partners LLC grew its holdings in Illumina by 14.3% during the 3rd quarter. Intellectus Partners LLC now owns 15,440 shares of the life sciences company’s stock valued at $2,014,000 after buying an additional 1,935 shares in the last quarter. Impax Asset Management Group plc grew its holdings in Illumina by 923.6% during the 3rd quarter. Impax Asset Management Group plc now owns 63,973 shares of the life sciences company’s stock valued at $8,343,000 after buying an additional 57,723 shares in the last quarter. Finally, ING Groep NV grew its holdings in shares of Illumina by 399.9% in the third quarter. ING Groep NV now owns 72,221 shares of the life sciences company’s stock valued at $9,418,000 after purchasing an additional 57,774 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ILMN has been the subject of a number of recent research reports. UBS Group raised their target price on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Argus raised shares of Illumina from a “hold” rating to a “buy” rating and set a $150.00 target price for the company in a report on Wednesday, August 28th. HSBC raised shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price for the company in a report on Thursday, October 17th. Canaccord Genuity Group raised their target price on shares of Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a report on Tuesday, November 5th. Finally, Scotiabank lowered their price target on Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a research report on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $164.00.

Illumina Stock Down 5.1 %

NASDAQ:ILMN opened at $135.05 on Friday. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a twelve month low of $92.69 and a twelve month high of $156.66. The stock has a fifty day simple moving average of $139.66 and a 200-day simple moving average of $124.31.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating the consensus estimate of $0.88 by $0.26. The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.33 earnings per share. Research analysts expect that Illumina, Inc. will post 4.11 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.